Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-05-03

FDA Approved: KADCYLA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for KADCYLA (ado-trastuzumab emtansine) submitted by Genentech, Inc., regarding an amendment to the product's labeling/i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Kadcyla (ado-trastuzumab emtansine)

Snippet

SUPPL AP for KADCYLA (ADO-TRASTUZUMAB EMTANSINE)